ENTA vs. GNFT, PRTA, ARDX, OCUL, GYRE, SYRE, AUTL, RLAY, COLL, and ARQT
Should you be buying Enanta Pharmaceuticals stock or one of its competitors? The main competitors of Enanta Pharmaceuticals include Genfit (GNFT), Prothena (PRTA), Ardelyx (ARDX), Ocular Therapeutix (OCUL), Gyre Therapeutics (GYRE), Spyre Therapeutics (SYRE), Autolus Therapeutics (AUTL), Relay Therapeutics (RLAY), Collegium Pharmaceutical (COLL), and Arcutis Biotherapeutics (ARQT). These companies are all part of the "medical" sector.
Genfit (NASDAQ:GNFT) and Enanta Pharmaceuticals (NASDAQ:ENTA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation.
Enanta Pharmaceuticals received 245 more outperform votes than Genfit when rated by MarketBeat users. However, 68.42% of users gave Genfit an outperform vote while only 56.47% of users gave Enanta Pharmaceuticals an outperform vote.
2.2% of Genfit shares are owned by institutional investors. Comparatively, 95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. 4.2% of Genfit shares are owned by insiders. Comparatively, 13.6% of Enanta Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Genfit has a beta of 1.22, indicating that its share price is 22% more volatile than the S&P 500. Comparatively, Enanta Pharmaceuticals has a beta of 0.6, indicating that its share price is 40% less volatile than the S&P 500.
Genfit has a net margin of 0.00% compared to Genfit's net margin of -180.76%. Enanta Pharmaceuticals' return on equity of 0.00% beat Genfit's return on equity.
Genfit has higher earnings, but lower revenue than Enanta Pharmaceuticals.
In the previous week, Genfit had 4 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 5 mentions for Genfit and 1 mentions for Enanta Pharmaceuticals. Genfit's average media sentiment score of 0.93 beat Enanta Pharmaceuticals' score of 0.62 indicating that Enanta Pharmaceuticals is being referred to more favorably in the news media.
Genfit presently has a consensus price target of $11.00, suggesting a potential upside of 160.66%. Enanta Pharmaceuticals has a consensus price target of $19.00, suggesting a potential upside of 22.42%. Given Enanta Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Genfit is more favorable than Enanta Pharmaceuticals.
Summary
Genfit beats Enanta Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Enanta Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ENTA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ENTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Enanta Pharmaceuticals Competitors List
Related Companies and Tools
Free ENTA Stock Alerts